JP2013525337A5 - - Google Patents

Download PDF

Info

Publication number
JP2013525337A5
JP2013525337A5 JP2013505533A JP2013505533A JP2013525337A5 JP 2013525337 A5 JP2013525337 A5 JP 2013525337A5 JP 2013505533 A JP2013505533 A JP 2013505533A JP 2013505533 A JP2013505533 A JP 2013505533A JP 2013525337 A5 JP2013525337 A5 JP 2013525337A5
Authority
JP
Japan
Prior art keywords
particles
sodium
surfactant
polyoxyethylene
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013505533A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013525337A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2011/000620 external-priority patent/WO2011131943A2/en
Publication of JP2013525337A publication Critical patent/JP2013525337A/ja
Publication of JP2013525337A5 publication Critical patent/JP2013525337A5/ja
Pending legal-status Critical Current

Links

JP2013505533A 2010-04-20 2011-04-20 医薬組成物 Pending JP2013525337A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1296MU2010 2010-04-20
IN1296/MUM/2010 2010-04-20
PCT/GB2011/000620 WO2011131943A2 (en) 2010-04-20 2011-04-20 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
JP2013525337A JP2013525337A (ja) 2013-06-20
JP2013525337A5 true JP2013525337A5 (https=) 2014-06-05

Family

ID=44625957

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013505533A Pending JP2013525337A (ja) 2010-04-20 2011-04-20 医薬組成物

Country Status (13)

Country Link
US (1) US20130302415A1 (https=)
EP (1) EP2560617A2 (https=)
JP (1) JP2013525337A (https=)
KR (1) KR20130076818A (https=)
CN (1) CN102985072A (https=)
AU (1) AU2011244783B2 (https=)
BR (1) BR112012026843A2 (https=)
CA (1) CA2796494A1 (https=)
GT (1) GT201200284A (https=)
NZ (1) NZ602955A (https=)
RU (1) RU2012149115A (https=)
WO (1) WO2011131943A2 (https=)
ZA (1) ZA201207670B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201115633D0 (en) 2011-09-09 2011-10-26 Univ Liverpool Compositions of efavirenz
US10646452B2 (en) * 2013-03-15 2020-05-12 New Jersey Institute Of Technology System and method for fabrication of uniform polymer films containing nano and micro particles via continuous drying process
IN2013MU03370A (https=) 2013-10-25 2015-09-25 Cipla Ltd
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
IN2014MU00916A (https=) * 2014-03-20 2015-09-25 Cipla Ltd
CN104224790A (zh) * 2014-09-28 2014-12-24 苏州普罗达生物科技有限公司 一种依法韦仑组合物及其制备方法
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
GB201515387D0 (en) * 2015-08-28 2015-10-14 Amazentis Sa Compositions
GB201515391D0 (en) * 2015-08-28 2015-10-14 Amazentis Sa Compositions
US11654112B2 (en) 2016-11-22 2023-05-23 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
AU2018306303A1 (en) * 2017-07-25 2020-02-20 Elektrofi, Inc. Formation of particles including agents
US20230040901A1 (en) * 2018-01-04 2023-02-09 PlantTec Medical GmbH Pharmaceutical composition for inhibiting postoperative adhesions
ES2732498B2 (es) * 2018-05-21 2020-04-27 Consejo Superior Investigacion Uso de efavirenz para el tratamiento de enfermedades de almacenamiento lipidico.
WO2019226969A1 (en) 2018-05-24 2019-11-28 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
JP7522655B2 (ja) * 2018-06-11 2024-07-25 大塚製薬株式会社 デラマニド含有組成物
EP3917500A2 (en) 2019-01-31 2021-12-08 Elektrofi, Inc. Particle formation and morphology
WO2021050953A1 (en) 2019-09-13 2021-03-18 Elektrofi, Inc. Compositions and methods for the delivery of therapeutic biologics for treatment of disease
AU2020395495B2 (en) * 2019-12-02 2024-05-09 Astrazeneca Ab Solid pharmaceutical formulations of 6-(2-chloro-6-methylpyridin-4-yl)-5-(-4-fluorophenyl)-1,2,4-triazin-3-amine
JP2023522627A (ja) 2020-04-17 2023-05-31 エレクトロフィ,インコーポレイテッド 連続的な液滴形成及び脱水によって粒子を形成する方法
US20210330683A1 (en) * 2020-04-20 2021-10-28 Poviva Corp. Compositions and methods for enhanced delivery of antiviral agents
CN112245400B (zh) * 2020-11-10 2023-01-20 蓝龙药业(北京)有限公司 一种依法韦仑微片剂、制备方法及其应用
CN114404377B (zh) * 2022-01-10 2023-07-25 安徽贝克生物制药有限公司 一种阿巴卡韦、拉米夫定、依非韦伦复方片及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72207C2 (uk) * 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
EP1332757B1 (en) * 1998-05-27 2012-06-13 Merck Sharp & Dohme Corp. Efavirenz compressed tablet formulation
CO5070643A1 (es) 1998-05-27 2001-08-28 Merck & Co Inc Formulacion en tabletas comprimidas
US20030124186A1 (en) * 2001-11-27 2003-07-03 Hussain Munir A. Efavirenz tablet formulation having unique biopharmaceutical characteristics
PE20070188A1 (es) * 2005-06-29 2007-03-16 Wyeth Corp Formulaciones de estrogenos conjugados y bazedoxifeno
US20080026062A1 (en) * 2006-07-31 2008-01-31 Isaac Farr Pharmaceutical compositions including nano-sized active agent
TWI405590B (zh) * 2007-04-06 2013-08-21 活效製藥股份有限公司 微粉碎化有機化合物粒子之製法
US20090088424A1 (en) * 2007-08-17 2009-04-02 Ilan Zalit Methods and compositions for controlling the bioavailability of poorly soluble drugs
JP4606444B2 (ja) * 2007-08-21 2011-01-05 アピ株式会社 アントシアニン含有経口投与用組成物及びその製造方法
WO2010068899A1 (en) * 2008-12-12 2010-06-17 Creighton University Nanoparticles comprising combinations of antiretroviral agents and use thereof
US10952965B2 (en) * 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
GB201006038D0 (en) * 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions

Similar Documents

Publication Publication Date Title
JP2013525337A5 (https=)
JP2013537182A5 (https=)
RU2012149115A (ru) Фармацевтическая композиция
JP2013538845A5 (https=)
CN104288154B (zh) 一种含有不同粒径范围的法匹拉韦药物组合物
RU2013113752A (ru) Фармацевтическая композиция
WO2013132457A3 (en) Nanocrystalline solid dispersion compositions and process of preparation thereof
CN104434809B (zh) 一种奥拉帕尼固体分散体制剂及其制备方法
AU2018253545A1 (en) Microcrystalline diketopiperazine compositions and methods
JP2014510704A5 (https=)
JP2016531913A5 (https=)
AR093449A1 (es) Polvo farmaceutico compuesto de nucleo-recubrimiento y procedimientos para producirlo
RU2013120275A (ru) Фармацевтическая композиция
MX337827B (es) Novedosos derivados polisacaridos y formas de administracion.
AR063983A1 (es) Formulacion de liberacion controlada de agonistas y antagonistas de piperazina -piperidina del receptor 5-ht1a que tienen una disolucion intestinal mejorada
MY159172A (en) Inhalable particles comprising tiotropium
CN103705520A (zh) 一种利伐沙班固体组合物的制备方法
WO2012053785A3 (ko) 타크롤리무스를 유효성분으로 함유하는 서방형 펠렛
JP2011251985A5 (https=)
CN104666262B (zh) 一种利伐沙班片
CN102406939A (zh) 提高难溶性药物溶解性能以提高生物利用度的方法
CN203124062U (zh) 一种具有三维空间分布喷嘴群的气流磨
CN104586814B (zh) 一种阿瑞匹坦胶囊
EA033291B1 (ru) Единица дозирования, содержащая рамиприл и бисопролола гемифумарат, способ ее получения и способ лечения гипертензии
WO2014154643A1 (en) Extended release formulations of metformin